ThreeD Cap (OTC:IDKFF) Stock, Quote.Headers.trade-ideas

ThreeD Capital Inc is a Canada-based venture capital firm. Principally, the company's operations relate to investing. It is focused on investments in companies in the junior resources, technology, and biotechnology markets.

THREED CAPITAL INC by ThreeD Capital Inc.

ThreeD Capital Inc

<p>Alternus Clean Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALCE#NASDAQ">ALCE</a>) ("Alternus" or the "Company"), a leading utility-scale transatlantic, clean energy independent power producer (IPP), has terminated its MIPSA with C2 Taiyo Fund I, LLP to acquire approximately 80MWp solar installations across 8 U.S. states, originally announced on May 1, 2024, due to seller's failure to meet the required closing conditions and fundamental changes in the portfolio of assets planned to be acquired.</p>


News

Contracts

ALCE

Alternus Clean Energy Has Terminated Its MIPSA With C2 Taiyo Fund I, LLP To Acquire ~80MWp Solar Installations Across 8 U.S. States, Originally Announced On May 1, 2024, Due To Seller's Failure To Meet The Required Closing Conditions And Fundamental Changes In The Portfolio Of Assets Planned To Be Acquired

WIIM

Nike shares are trading higher after the company announced Elliot Hill will take over as the new President and CEO. John Donahoe will retire from his position.

TechnipFMC Awarded Two Subsea Contracts By Petrobras For Brazil's Pre-Salt Fields; First Contract Is Between $250M-$500M And Second Is Between $75M-$250M

Earnings

GNFT

CORRECTION: Genfit H1 2024 Adj. EPS €0.53; Revenues And Other Income €61.199M

<p>Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 33% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $562,711, and 5 were calls, valued at $259,716.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $60.0 to $100.0 for Moderna during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of 2,026.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $60.0 to $100.0 over the last 30 days.</p>
<h3>Moderna Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726777077_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$25.9</td>
<td>$24.35</td>
<td>$25.9</td>
<td>$90.00</td>
<td>$388.5K</td>
<td>1.9K</td>
<td style="text-align: right;">150</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$13.3</td>
<td>$13.25</td>
<td>$13.3</td>
<td>$70.00</td>
<td>$81.1K</td>
<td>108</td>
<td style="text-align: right;">123</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$31.0</td>
<td>$30.85</td>
<td>$31.0</td>
<td>$100.00</td>
<td>$65.1K</td>
<td>0</td>
<td style="text-align: right;">609</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.66</td>
<td>$2.65</td>
<td>$2.65</td>
<td>$60.00</td>
<td>$59.3K</td>
<td>1.6K</td>
<td style="text-align: right;">233</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.6</td>
<td>$3.55</td>
<td>$3.55</td>
<td>$80.00</td>
<td>$58.5K</td>
<td>702</td>
<td style="text-align: right;">536</td>
</tr>
</tbody>
</table>
</p>
<h3>About Moderna</h3>
<p>Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.</p>
<p>Following our analysis of the options activities associated with Moderna, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>Trading volume stands at 5,013,059, with MRNA's price down by -2.52%, positioned at $68.1.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 42 days.</li>
</ul>
<h3>What Analysts Are Saying About Moderna</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $82.4.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Sector Perform, setting a price target of $75.<br />
&#x2A; An analyst from RBC Capital has decided to maintain their Sector Perform rating on Moderna, which currently sits at a price target of $75.<br />
&#x2A; An analyst from Jefferies has revised its rating downward to Hold, adjusting the price target to $65.<br />
&#x2A; An analyst from HSBC upgraded its action to Hold with a price target of $82.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Moderna, targeting a price of $115. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

MRNA

Behind the Scenes of Moderna's Latest Options Trends

Offerings

KOPN

Kopin Corporation Announces Public Offering of Common Stock and Pre-Funded Warrants, Plans to Use Proceeds for Corporate Purposes and Potential Litigation Payments; Size Not Disclosed

<p>Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) reported quarterly earnings of $0.57 per share. This is a 226.67 percent increase over losses of $(0.45) per share from the same period last year.  The company reported $63.49 million in sales this quarter. This is a 281.83 percent increase over sales of $16.63 million the same period last year.</p>


Genfit H1 EPS $0.57 Up From $(0.45) YoY, Sales $63.49M Up From $16.63M YoY (Converted To USD)

Management

TIGO

Millicom International Cellular Appoints Maxime Lombardini As Interim Chair Of The Board

Nike Says Elliott Hill To Join Nike Board And Executive Committee

<p>Cryptocurrency markets are trading 5.9% higher to $2.19 trillion as crypto short liquidations spiked to the highest level since Aug. 23.</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price</strong></td>
<td>G<strong>ains +/-</strong></td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$63,485.74</td>
<td>+5.3%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,467.60</td>
<td>+6.6%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$143.74</td>
<td>+10.8%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1062</td>
<td>+5%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.0000142</td>
<td>+6.3%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p>Notable Statistics:</p>
<ul>
<li>IntoTheBlock data shows a 1% drop in large transaction volume and a 5.7% decline in daily active addresses. However, exchanges netflows narrowed by 278.4%. With Bitcoin prices racing beyond the $61,000 mark, 88% of Bitcoin holders are in profit, while 12% are at breakeven.</li>
<li>Coinglass data shows 61,634 traders liquidated in the past 24 hours for $190.39 million, with short liquidations coming in at $117.6 million, the highest level since Aug. 23.</li>
</ul>
<p>Notable Developments:</p>
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40943186/cybercriminals-busted-for-243m-crypto-heist-they-spent-hundreds-of-thousands-in-night-club">Cybercriminals Busted For $243M Crypto Heist: They Spent Hundreds Of Thousands In Night Clubs And On Luxury Gifts</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40942924/whats-going-on-with-coinbase-stock">What&#8217;s Going On With Coinbase Stock?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40944865/jade-city-to-democratize-access-to-50b-jade-market-with-tokenization-platform">Jade City To Democratize Access To $50B Jade Market With Tokenization Platform</a></li>
</ul>
<p>Top Gainers:</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td>Popcat (SOL) (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POPCAT</a>)</td>
<td>$0.8976</td>
<td>+28.2%</td>
</tr>
<tr>
<td>Sei (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SEI</a>)</td>
<td>$0.3344</td>
<td>+19.9%</td>
</tr>
<tr>
<td>Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>)</td>
<td>$1.77</td>
<td>+18.5%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Trader Notes: </strong>With Bitcoin prices chasing the $63,000 mark, Cold Blooded Shiller predicts that if this move breaks to the upside, &#8220;expect this area to be a sweep with a fast response back.&#8221; He suggests keeping note of the $61,500 level.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">If we get the LTF <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> correction I think the reaction around $61.5k will be important. <br /><br />If this move is going to break HTF structure to the upside I&#39;d expect this area to be a sweep with a fast response back. (The good ol&#39; V-reversal days) <a href="https://t.co/0nowzEJ8dL">pic.twitter.com/0nowzEJ8dL</a></p>
<p>&mdash; Cold Blooded Shiller (@ColdBloodShill) <a href="https://twitter.com/ColdBloodShill/status/1836847538164363288?ref_src=twsrc%5Etfw">September 19, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p><figcaption class="wp-element-caption">Crypto trader Scient <a href="https://x.com/Crypto_Scient/status/1836849315878256780">states</a> that this is that part of cycle where Bitcoin cools off, &#8220;does a bit of correction and altcoins take the lead.&#8221; However, after Bitcoin&#8217;s consolidation, it takes the lead again, makes the next leg higher and altcoins slow down. </figcaption></p></figure></p>
<p>Stockmoney Lizards marks this price movement as the beginning of the &#8220;final cycle pump&#8221; and expects the cycle top around September to October 2025 between $200,000 and $260,000.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a>: The Final Cycle Pump Begins<br /><br />We are entering what could be the final pump of this Bitcoin cycle. The cycle top is expected around September to October 2025. My personal price target for Bitcoin is between $200,000 and $260,000.<br /><br />Legend:<br />Here, you can see the last three… <a href="https://t.co/f7BTzM8YyM">pic.twitter.com/f7BTzM8YyM</a></p>
<p>&mdash; Stockmoney Lizards (@StockmoneyL) <a href="https://twitter.com/StockmoneyL/status/1836835839340597600?ref_src=twsrc%5Etfw">September 19, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>What&#8217;s Next</strong>: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40932192/trump-pays-up-for-smash-burgers-and-diet-cokes-with-bitcoin-during-new-york-campaign-halt-"><strong>Trump Pays Up For Smash Burgers And Diet Cokes With Bitcoin During New York Campaign Halt — Move Hailed As &#8216;One Of The Most Historic Transactions&#8217;</strong></a></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$POPCAT

$SEI

$SHIB

$SOL

$WIF

Bitcoin, Ethereum, Dogecoin Surge: Has The 'Final Cycle Pump' Really Started?

Nike, Inc. Board Of Directors Announces Long-time Nike Veteran Elliott Hill To Return As President And Chief Executive Officer John Donahoe To Retire From Nike

Guidance

NWTN

NWTN Suspends Rabdan Vehicle Production Following UAE Authority's Directive, Rebadges 320 Vehicles, Expects $17M Inventory Impairment, Reduces Workforce by 57%, and Explores New Partnerships Amid Challenges

AENT

Alliance Entertainment shares are trading higher after the company reported better-than-expected full-year 2024 adjusted EPS results.

Financing

Simon Property Group Amended, Restated And Extended $3.5B Revolving Credit Facility

<p><i>TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial</i><br /><br />&nbsp;</p>
<p><i>Results to be presented at the American Heart Association (AHA) Scientific Sessions in November 2024</i></p>
<p><i>Phase 1b single dose hemodynamic proof-of-concept clinical trial in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) escalated to the highest dose of TX45 (3 mg/kg) based on favorable tolerability profile observed at lower doses, with topline trial results expected in the second quarter of 2025</i></p>
<p>WATERTOWN, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced favorable Phase 1a topline data for its lead asset TX45, a long-acting, potentially best-in-class relaxin. TX45 is being developed for the treatment of Group 2 PH-HFpEF.</p>


Biotech

General

TECX

Tectonic Therapeutic Announces Phase 1a Safety, Tolerability And PK/PD Results For Lead Program TX45; TX45 Was Well-tolerated With No Observed Immunogenicity, And Demonstrated A Favorable PK/PD Relationship Which Was Used To Identify Doses For The Phase 2 Clinical Trial

Arq shares are trading lower after the company announced a proposed public offering of common stock, details not disclosed.

<p>iPower (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.01 by 200 percent.  The company reported quarterly sales of $19.500 million which missed the analyst consensus estimate of $21.300 million by 8.45 percent.  This is a 16.66 percent decrease over sales of $23.399 million the same period last year.</p>


Earnings Beats

Earnings Misses

iPower Q4 2024 Adj. EPS $0.03 Beats $0.01 Estimate, Sales $19.5M Miss $21.300M Estimate

<p>Research Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSSS#NASDAQ">RSSS</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent.  The company reported quarterly sales of $12.133 million which beat the analyst consensus estimate of $11.852 million by 2.37 percent.  This is a 21.82 percent increase over sales of $9.960 million the same period last year.</p>


RSSS

Research Solutions Q4 2024 GAAP EPS $(0.09) Misses $(0.08) Estimate, Sales $12.133M Beat $11.852M Estimate

<p><strong>Sony Group Corp. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) has <a href="https://blog.playstation.com/2024/09/19/celebrating-30-years-of-playstation-with-a-nostalgic-look/">introduced</a> a special 30th Anniversary Collection to mark three <a href="https://www.benzinga.com/topic/playstation">decades of PlayStation. </a></p>
<p>The collection includes a PS5 Pro bundle, which is particularly notable due to its limited availability. Only 12,300 units of this bundle will be released worldwide. </p>
<p>The bundle features the PS5 Pro console with a design inspired by the original PSOne. It includes a vertical stand, a charging station, and the DualSense Edge controller. </p>
<p><strong>See Also: <a href="https://www.benzinga.com/general/gaming/24/09/40883757/sony-ceo-confirms-consoles-are-still-core-to-playstations-future">Sony CEO Confirms Consoles Are Still &#8216;Core&#8217; To PlayStation&#8217;s Future</a></strong></p>
<p>Additionally, the bundle comes with a retro-style PlayStation controller cable connector, four cable ties designed with classic symbols, and other items such as a sticker, poster, and paperclip.</p>
<h3 class="wp-block-heading"><strong>PlayStation 5 Slim Digital Edition</strong></h3>
<p>Another offering in the collection is the PlayStation 5 Slim Digital Edition. This model includes a matching disc drive cover, though the disc drive must be purchased separately. </p>
<p>The Slim Digital Edition comes with a regular DualSense controller, a vertical stand, and similar retro-themed accessories as the PS5 Pro bundle.</p>
<h3 class="wp-block-heading"><strong>Preorder Information</strong></h3>
<p>Preorders for the 30th Anniversary Collection will begin on Sept. 26, 2024, but Sony has not yet announced the prices for any of these items. Preorders will be available through PlayStation Direct for individuals with a PlayStation Network account.</p>
<p>For regions where PlayStation Direct is not available, participating retailers will also offer preorders starting on the same date. The PS5 Digital Edition will be available for preorder through these retailers from October 10, 2024.</p>
<p>The DualSense controllers, including both the standard and Edge versions, will be available separately for those interested in the retro-themed design without purchasing the entire bundle.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/09/40907983/september-playstation-plus-lineup-whats-coming-and-whats-leaving">September PlayStation Plus Lineup: What&#8217;s Coming And What&#8217;s Leaving</a></li>
</ul>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Introducing the PlayStation 30th Anniversary Collection" width="500" height="281" src="https://www.youtube.com/embed/amdZnHooTkk?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><em>Image courtesy of Sony.</em></p>


Gaming

Sony Group Corporation American Depositary Shares

SONY

PlayStation Celebrates 30 Years With Retro-Themed PS5 Pro And Slim Editions

<p><i>Confirms Continuation of Evaluation of Strategic Alternatives</i></p>
<p>MEI Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) (the "Company") today reported results for its fiscal year ended June 30, 2024.</p>
<p>Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer &amp; Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and evaluation of that process. As part of the review of strategic alternatives, the Company will consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities.</p>
<p>To best preserve the Company's existing cash, the Company commenced a reduction-in-force on August 1, 2024, which will continue in stages as the Company's operational and strategic direction evolves. Additionally, while the Company has discontinued the clinical development of voruciclib, certain non-clinical activities related to the Company's drug candidates continue to be conducted.</p>
<p>There can be no assurance the exploration of strategic alternatives will result in any agreements or transactions, or, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not expect to disclose developments with respect to this process unless or until the evaluation of strategic alternatives has been completed or the Board of Directors has concluded disclosure is appropriate or legally required.</p>
<p>As of June 30, 2024, MEI had $38.3 million in cash, cash equivalents, and short-term investments with no outstanding debt.</p>


MEIP

MEI Pharma Says As Of June 30, 2024, Have $38.3M In Cash, Cash Equivalents, And Short-Term Investments With No Outstanding Debt; Confirms Continuation Of Evaluation Of Strategic Alternatives

ThreeD Capital reports quarterly results

ThreeD Capital says its NAV per share as of Dec. 31 is $0.83

ThreeD Capital reports Q2 results

ThreeD Capital announces unaudited Feb 29 net asset value per share of $0.85

ThreeD Capital says unaudited March 31 NAV per share was $0.88

ThreeD Capital announced net asset value per share was C$0.89 as of March 31, 2024

ThreeD Capital announces C$1.51M private placement equity financing

ThreeD Capital announces net asset value per share of C$0.92 as of June 30, 2024

ThreeD Capital to conduct normal course issuer bid

IDKFF

Press Releases

ThreeD Capital Inc. Announces Unaudited June 30, 2024 Net Asset Value Per Share - $0.92

ThreeD Capital Inc. Announces Securities Purchase Agreement with Sariel Diagnostics Corp.

ThreeD Capital Inc. Issues Early Warning Report in Connection with the Acquisition of Securities of AI/ML Innovations Inc.

ThreeD Capital Inc. Issues Early Warning Report in Connection With the Acquisition of Securities of infinitii ai inc.

ThreeD Capital Inc. Announces Agreement with Passive Income Investor Inc. and New Videos to ThreeD's Youtube Channel

ThreeD Capital Inc. Announces Unaudited July 31, 2024 Net Asset Value Per Share - $0.86

ThreeD Capital Inc. Announces Completion of Securities Purchase Agreement with Sariel Diagnostics Corp.

ThreeD Capital Inc. Issues Early Warning Report in Connection with Acquisition of Securities of Quebec Innovative Materials Corp.

ThreeD Capital Inc. Announces Unaudited August 31, 2024 Net Asset Value Per Share - $0.86

ThreeD Capital Inc. Announces Its Intention To Effect A Normal Course Issuer Bid

CSE:IDK

CSE:QIMC

ThreeD Cap

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

ThreeD Cap

ThreeD Cap (IDKFF) Forecast

ThreeD Cap (OTC:IDKFF) Stock, Quote.Headers.trade-ideas